Skip to main content

Table 3 Stratified analyses for the CKD risk associated with APOA5 polymorphisms by BMI levels

From: Polymorphisms of genes involved in lipid metabolism and risk of chronic kidney disease in Japanese - cross-sectional data from the J-MICC study

Proportion of minor heterozygous plus homozygous (among subjects with all genotypes)

CKD (+)

CKD (-)

OR*

95% CI*

P interaction #

(n = 564)

(n = 2,704)

   

Genotype

BMI

N

(%)

N

(%)

   

APOA5 T-1131C

       

(rs662799)

        
 

≥ 30

15/16

(93.8)

54/95

(56.8)

12.39

1.55-99.09

 
 

< 30

328/548

(59.9)

1,453/2,609

(55.7)

1.21

0.999-1.47

0.028

APOA5 T1259C

       

(rs2266788)

        
 

≥ 30

13/16

(81.3)

50/95

(52.6)

3.68

0.97-13.93

 
 

< 30

269/548

(49.1)

1,217/2,609

(46.6)

1.14

0.95-1.38

0.079

  1. *aOR: adjusted odds ratio (adjusted for age and sex); 95% CI: 95% confidence interval.
  2. #OR for interaction =10.43 (95% CI: 1.29-84.19) for APOA5 rs662799, and 3.36 (95% CI: 0.87-13.01) for APOA5 rs2266788.